# US 2024/0199554 A1 · Inhibitors of receptor interacting protein kinase i for the treatment of disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199554 A1
- Document ID: US20240199554A1
- Status: Published application
- Kind: A1
- Application number: 18/355,792
- Filed: 2023-07-20
- Published: 2024-06-20
- Earliest claimed: 2019-09-27
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Richard T. LEWIS; Matthew Michael HAMILTON; William J. RAY; Fernando ALVAREZ; Dana E. PFAFFINGER; Naphtali REYNA; Jason CROSS; Suyambu Kesava Vijayan RAMASWAMY
- Web page: https://patentgrep.com/patent/US20240199554A1

## CPC

- C07D 231/06: having one double bond between ring members or between a ring member and a non-ring member
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61K 31/415: 1,2-Diazoles
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/4245: Oxadiazoles
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4965: Non-condensed pyrazines
- A61K 31/497: containing further heterocyclic rings
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D 207/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/08: linked by a carbon chain containing alicyclic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 413/08: linked by a carbon chain containing alicyclic rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

## Claims

### Claim at position 1

-67. (canceled)

### Claim 68

A method of inhibition of RIPK1 comprising contacting RIPK1 with a compound of structural Formula I:
or a salt thereof, wherein:
X is alkylene and is optionally substituted with one or more R7,
or X is chosen from carbamoyl, carbonyl, and a bond;
R1a and R1b, together with the intervening nitrogen, combine to form a pyrazoline, which is optionally substituted with one R3, and which is optionally substituted with one or more R4;
R2 is chosen from hydrogen, hydroxy, cyano, and halo,
or R2 is chosen from alkyl, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, (cycloalkyl)oxy, (heterocycloalkyl)oxy, (aryl)oxy, (heteroaryl)oxy, (alkyl)carbonyl, (cycloalkyl)carbonyl, (heterocycloalkyl)carbonyl, (aryl)carbonyl, (alkyl)amino, (cycloalkyl)amino, (heterocycloalkyl)amino, (aryl)amino, and (heteroaryl)amino, any of which is optionally substituted with one or more R5;
R3 is chosen from aryl, (aryl)oxy, heteroaryl, (heteroaryl)oxy, cycloalkyl, and heterocycloalkyl, any of which is optionally substituted with one or more R6;
each R4 is independently chosen from alkyl, halo, cyano, and hydroxy;
each R5 is independently chosen from halo, cyano, amido, alkyl, alkoxy, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, haloalkyl, oxo, P(O)(CH3)2, SO2CH3, aryl optionally substituted with one or more alkyl, and heteroaryl optionally substituted with one or more alkyl;
two R5, together with the intervening atoms, optionally combine to form a cycloalkyl or heterocycloalkyl;
each R6 is independently chosen from halo, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, and haloalkoxy; and
each R7 is independently chosen from alkyl, cyano, halo, and hydroxy.

### Claim 69

A method of treatment of a RIPK1-mediated disease comprising the administration of a therapeutically effective amount of a compound as of structural Formula I:
or a salt thereof, wherein:
X is alkylene and is optionally substituted with one or more R7,
or X is chosen from carbamoyl, carbonyl, and a bond;
R1a and R1b, together with the intervening nitrogen, combine to form a pyrazoline, which is optionally substituted with one R3, and which is optionally substituted with one or more R4;
R2 is chosen from hydrogen, hydroxy, cyano, and halo,
or R2 is chosen from alkyl, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, (cycloalkyl)oxy, (heterocycloalkyl)oxy, (aryl)oxy, (heteroaryl)oxy, (alkyl)carbonyl, (cycloalkyl)carbonyl, (heterocycloalkyl)carbonyl, (aryl)carbonyl, (alkyl)amino, (cycloalkyl)amino, (heterocycloalkyl)amino, (aryl)amino, and (heteroaryl)amino, any of which is optionally substituted with one or more R5;
R3 is chosen from aryl, (aryl)oxy, heteroaryl, (heteroaryl)oxy, cycloalkyl, and heterocycloalkyl, any of which is optionally substituted with one or more R6;
each R4 is independently chosen from alkyl, halo, cyano, and hydroxy;
each R5 is independently chosen from halo, cyano, amido, alkyl, alkoxy, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, haloalkyl, oxo, P(O)(CH3)2, SO2CH3, aryl optionally substituted with one or more alkyl, and heteroaryl optionally substituted with one or more alkyl;
two R5, together with the intervening atoms, optionally combine to form a cycloalkyl or heterocycloalkyl;
each R6 is independently chosen from halo, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, and haloalkoxy; and
each R7 is independently chosen from alkyl, cyano, halo, and hydroxy, to a patient in need thereof.

### Claim 70 (depends on 69)

The method as recited in claim 69, wherein said disease is a neurological disease.

### Claim 71

(canceled)

### Claim 72 (depends on 70)

The method as recited in claim 70, wherein said neurological disease is chosen from Multiple Sclerosis, Neimann-Pick disease, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Lewy body dementia, frontotemporal dementia, and glutamine expansion diseases such as Huntington's disease, Kennedy's disease, spinocerebellar ataxia.

### Claim 73 (depends on 69)

The method as recited in claim 69, wherein said disease is a neuropathy.

### Claim 74 (depends on 73)

The method as recited in claim 73, wherein said neuropathy is chosen from diabetic neuropathy and chemotherapy induced neuropathy.

### Claim 75 (depends on 69)

The method as recited in claim 69, wherein said disease is a retinal disease.

### Claim 76 (depends on 75)

The method as recited in claim 75, wherein said retinal disease is chosen from macular degeneration and retinitis.

### Claim 77 (depends on 69)

The method as recited in claim 69, wherein said disease is an autoimmune disorder.

### Claim 78 (depends on 77)

The method as recited in claim 77, wherein said autoimmune disorder is chosen from ulcerative colitis, rheumatoid arthritis, psoriasis, lupus, and inflammatory bowel disease.

### Claim 79 (depends on 69)

The method as recited in claim 69, wherein said disease is an inflammatory disease.

### Claim 80

(canceled)

### Claim 81 (depends on 69)

The method as recited in claim 69, wherein said disease is cancer.

### Claim 82

(canceled)

### Claim 83

(canceled)

### Claim 84

A method of treatment of injury to the CNS comprising the administration of a therapeutically effective amount of a compound of structural Formula I:
or a salt thereof, wherein:
X is alkylene and is optionally substituted with one or more R7,
or X is chosen from carbamoyl, carbonyl, and a bond;
R1a and R1b, together with the intervening nitrogen, combine to form a pyrazoline, which is optionally substituted with one R3, and which is optionally substituted with one or ore R4;
R2 is chosen from hydrogen, hydroxy, cyano, and halo,
or R2 is chosen from alkyl, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, (cycloalkyl)oxy, (heterocycloalkyl)oxy, (aryl)oxy, (heteroaryl)oxy, (alkyl)carbonyl, (cycloalkyl)carbonyl, (heterocycloalkyl)carbonyl, (aryl)carbonyl, (alkyl)amino, (cycloalkyl)amino, (heterocycloalkyl)amino, (aryl)amino, and (heteroaryl)amino, any of which is optionally substituted with one or more R5;
R3 is chosen from aryl, (aryl)oxy, heteroaryl, (heteroaryl)oxy, cycloalkyl, and heterocycloalkyl, any of which is optionally substituted with one or more R6;
each R4 is independently chosen from alkyl, halo, cyano, and hydroxy;
each R5 is independently chosen from halo, cyano, amido, alkyl, alkoxy, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, haloalkyl, oxo, P(O)(CH3)2, SO2CH3, aryl optionally substituted with one or more alkyl, and heteroaryl optionally substituted with one or more alkyl;
two R5, together with the intervening atoms, optionally combine to form a cycloalkyl or heterocycloalkyl;
each R6 is independently chosen from halo, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, and haloalkoxy; and
each R7 is independently chosen from alkyl, cyano, halo, and hydroxy, to a patient in need thereof.

### Claim 85

(canceled)

### Claim 86

(canceled)

### Claim 87

(canceled)

### Claim 88

(canceled)

### Claim 89

(canceled)

### Claim 90 (depends on 69)

The method as recited in claim 69, or a salt thereof, wherein X is alkylene and is optionally substituted with one or more R7.

### Claim 91 (depends on 69)

The method as recited in claim 69, wherein the compound is of structural Formula II:
or a salt thereof, wherein:
m is chosen from 0 and 1;
n is chosen from 0, 1, 2, and 3;
W is chosen from C(R6a) and N;
X is alkylene and is optionally substituted with one or more R7,
or X is chosen from carbamoyl, carbonyl, and a bond;
Y is chosen from NH and N;
Y and the intervening carbons and nitrogen combine to form a pyrazoline;
R2 is chosen from hydrogen, hydroxy, cyano, and halo,
or R2 is chosen from alkyl, amino, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, (cycloalkyl)oxy, (heterocycloalkyl)oxy, (aryl)oxy, (heteroaryl)oxy, (alkyl)carbonyl, (cycloalkyl)carbonyl, (heterocycloalkyl)carbonyl, (aryl)carbonyl, (alkyl)amino, (cycloalkyl)amino, (heterocycloalkyl)amino, (aryl)amino, and (heteroaryl)amino, any of which is optionally substituted with one or more R5;
each R4 is independently chosen from halo, cyano, and hydroxy;
each R5 is independently chosen from halo, cyano, amido, alkyl, alkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, haloalkyl, oxo, P(O)(CH3)2, SO2CH3, aryl optionally substituted with one or more alkyl, and heteroaryl optionally substituted with one or more alkyl;
two R5, together with the intervening atoms, optionally combine to form a cycloalkyl or heterocycloalkyl;
each R6 is independently chosen from halo, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, and haloalkoxy;
R6a is chosen from H, halo, alkyl, cyano, alkoxy, hydroxy, haloalkyl, and haloalkoxy; and
each R7 is independently chosen from alkyl, cyano, halo, and hydroxy.

### Claim 92 (depends on 91)

The method as recited in claim 91, or a salt thereof, wherein Y is N and m is 0.

### Claim 93 (depends on 69)

The method as recited in claim 69, wherein the compound is of structural Formula (VII):
or a salt thereof, wherein:
W1 is chosen from C(R6b) and N;
W2 is chosen from C(R6e) and N;
Y is chosen from NH and N;
Y and the intervening carbons and nitrogen combine to form a pyrazoline;
Y1 is chosen from C(R5b) and N;
Y2 is chosen from C(R5c) and N;
Z is chosen from O, NH, and N(CH3);
R4a is chosen from H, halo, cyano, and hydroxy;
R5a, R5b, R5c, and R5d are independently chosen from H, halo, cyano, amido, alkyl, alkoxy, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, haloalkyl, P(O)(CH3)2, SO2CH3, aryl optionally substituted with one or more alkyl, and heteroaryl optionally substituted with alkyl;
R6a, R6b, R6c, R6d, and R6e are independently chosen from H, halo, alkyl, cycloalkyl, cyano, alkoxy, hydroxy, haloalkyl, hydroxyalkyl, and haloalkoxy; and
R7a is chosen from H, alkyl, cyano, halo, and hydroxy.

### Claim 94 (depends on 93)

The method as recited in claim 93, or a salt thereof, wherein R5a, R5b, R5c, and R5d are independently chosen from H, halo, cyano, CONH2, C1-6alkyl, C1-6alkoxy, cyanoC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxyC1-6alkyl, C3-7cycloalkyl, haloC1-6alkyl, P(O)(CH3)2, SO2CH3, and 5- to 7-membered heteroaryl optionally substituted with methyl.

### Claim 95 (depends on 69)

The method as recited in claim 69, wherein the compound is chosen from:
or a salt thereof.

### Claim 96 (depends on 69)

The method as recited in claim 69, wherein the compound is
